Customize your JAMA Network experience by selecting one or more topics from the list below.
Hepatitis C poses a challenging dilemma for physicians and patients. On one hand, as well demonstrated by this article, it is a disease with serious morbidity and mortality. The desire to treat patients to prevent these consequences is great. But, the treatments that we have had available are not very effective in clearing the infection, result in serious adverse effects including making patients feel sick during a prolonged treatment course, and are expensive. For these reasons neither I nor my patients have been very enthusiastic about treatment.
Further complicating the issue, I have been reluctant to treat patients who are healthy despite their hepatitis C infection because I have felt that they had time to wait until better treatments were available. Conversely, I have been reluctant to treat patients who have already experienced severe liver damage from hepatitis C because I have feared that they could not tolerate the adverse effects of treatment and because it is unclear whether even if the virus is suppressed their clinical function would improve. This has left me, and many clinicians, in the odd position of feeling that patients are either too healthy or too sick for hepatitis C treatment. It undoubtedly explains why in this Veterans Affairs cohort only 24% of patients had received treatment at any time.
Katz MH. Hepatitis C Treatment: Stuck Between a Rock and a Hard Place but Hoping to Be Rescued Soon. JAMA Intern Med. 2014;174(2):212. doi:10.1001/jamainternmed.2013.12418
Create a personal account or sign in to: